(Q46183954)

20 December 2017

title

Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment (English)

1 reference

20 December 2017

1 reference

K Dede

1

1 reference

20 December 2017

T Mersich

2

1 reference

20 December 2017

I Besznyák

3

1 reference

20 December 2017

A Zaránd

4

1 reference

20 December 2017

F Salamon

5

1 reference

20 December 2017

Z S Baranyai

6

1 reference

20 December 2017

L Landherr

7

1 reference

20 December 2017

F Jakab

8

1 reference

20 December 2017

A Bursics

9

1 reference

20 December 2017

publication date

19 February 2013

1 reference

20 December 2017

Pathology Oncology Research

published in

1 reference

20 December 2017

volume

19

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

501-508

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1007/s12253-013-9608-2

exact match

0 references

cites work

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

The timing of chemotherapy and surgery for the treatment of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Chemotherapy before liver resection of colorectal metastases: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9608-2

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

21 January 2018

1 reference

12 December 2020

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases

1 reference

12 December 2020

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

1 reference

12 December 2020

Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery

1 reference

12 December 2020

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

1 reference

12 December 2020

10.1007/S12253-013-9608-2

Identifiers

DOI

1 reference

20 December 2017

release_hv45jepqw5chdhvhvtzsf6i7qm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hv45jepqw5chdhvhvtzsf6i7qm

24 November 2022

mapped directly with Wikidata item

PubMed ID

23420304

1 reference

20 December 2017